497 related articles for article (PubMed ID: 25822862)
21. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection.
Sun HT; Zhang SL; Liu K; Zhou JJ; Wang XX; Shen TT; Song XH; Guo YL; Wang XL
J Magn Reson Imaging; 2019 Aug; 50(2):397-409. PubMed ID: 30589158
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
23. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
24. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
[TBL] [Abstract][Full Text] [Related]
25. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
27. A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.
Liang W; Yang P; Huang R; Xu L; Wang J; Liu W; Zhang L; Wan D; Huang Q; Lu Y; Kuang Y; Niu T
Clin Cancer Res; 2019 Jan; 25(2):584-594. PubMed ID: 30397175
[TBL] [Abstract][Full Text] [Related]
28. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.
Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
[TBL] [Abstract][Full Text] [Related]
29. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
30. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
31. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors.
Kim M; Lee S; Lee J; Park SH; Park JO; Park YS; Kang WK; Kim ST
Cancer Res Treat; 2016 Jan; 48(1):153-61. PubMed ID: 25779359
[TBL] [Abstract][Full Text] [Related]
32. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
[TBL] [Abstract][Full Text] [Related]
33. Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis.
Gaitanidis A; Patel D; Nilubol N; Tirosh A; Sadowski S; Kebebew E
Ann Surg Oncol; 2018 Jan; 25(1):122-130. PubMed ID: 29134377
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.
Jensen KH; Hilsted L; Jensen C; Mynster T; Rehfeld JF; Knigge U
Scand J Gastroenterol; 2013 Jan; 48(1):70-7. PubMed ID: 23094948
[TBL] [Abstract][Full Text] [Related]
35. Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: a multicenter study.
Li J; Huang L; Liao C; Liu G; Tian Y; Chen S
BMC Cancer; 2023 Jun; 23(1):529. PubMed ID: 37296397
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
37. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
[TBL] [Abstract][Full Text] [Related]
38. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
39. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
[TBL] [Abstract][Full Text] [Related]
40. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
